scispace - formally typeset
G

Garth J. S. Cooper

Researcher at University of Auckland

Publications -  309
Citations -  17579

Garth J. S. Cooper is an academic researcher from University of Auckland. The author has contributed to research in topics: Amylin & Insulin. The author has an hindex of 63, co-authored 299 publications receiving 16490 citations. Previous affiliations of Garth J. S. Cooper include Manchester Academic Health Science Centre & University of Manchester.

Papers
More filters
Journal ArticleDOI

Visceral Adiposity and Glucoregulatory Peptides are Associated with Susceptibility to Type 2 Diabetes: The TOFI_Asia Study.

TL;DR: Ethnic differences in fat deposition contribute to type 2 diabetes and identification of biomarkers that underpin dysglycemia are needed for better‐targeted prevention and treatment.
Journal ArticleDOI

Synthesis of the IGF-II-like hormone vesiculin using regioselective formation of disulfide bonds

TL;DR: Preliminary studies indicate Vesiculin, a novel IGF-II-like protein was recently isolated from the secretory granules of murine β-cells, is capable of signalling via the insulin receptor (IR)/insulin-like growth factor receptor 1(IGF1R) family giving it the potential to elicit both metabolic and mitogenic responses in the beta-cell.
Journal ArticleDOI

Glicentin-related pancreatic polypeptide inhibits glucose-stimulated insulin secretion from the isolated pancreas of adult male rats

TL;DR: Rat GRPP and rGRPP‐LP did not affect glucose output from the liver, but both elicited potent inhibition of glucose‐stimulated insulin secretion from the rat pancreas, suggesting they may be novel regulators of insulin secretion.

Applied nutritional investigation Postprandial response of adiponectin, interleukin-6, tumor necrosis factor-, and C-reactive protein to a high-fat dietary load

TL;DR: Acute changes in the content of saturated and unsaturated fatty acids had no adverse effect on postprandial circulation of the adipose-related factors adiponectin, IL-6, TNF- ,o r high-sensitivity CRP.
Patent

Amylin activity assays

TL;DR: In this paper, methods are disclosed for use in identifying or assaying compounds which can inhibit or simulate the ability of amylin to cause hyperlactemia and/or hyperglycemia in in vivo biological models.